Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.

Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y.

Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.

2.

Undifferentiated Wharton's Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice.

Tsai PJ, Wang HS, Lin GJ, Chou SC, Chu TH, Chuan WT, Lu YJ, Weng ZC, Su CH, Hsieh PS, Sytwu HK, Lin CH, Chen TH, Shyu JF.

Cell Transplant. 2015;24(8):1555-70. doi: 10.3727/096368914X683016. Epub 2014 Jul 15.

PMID:
25198179
3.

Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus.

Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y.

Endocr J. 2013;60(3):347-57. Epub 2012 Nov 16.

4.

Effect and mechanisms of human Wharton's jelly-derived mesenchymal stem cells on type 1 diabetes in NOD model.

Hu J, Wang Y, Wang F, Wang L, Yu X, Sun R, Wang Z, Wang L, Gao H, Fu Z, Zhao W, Yan S.

Endocrine. 2015 Feb;48(1):124-34. doi: 10.1007/s12020-014-0219-9. Epub 2014 Mar 4.

PMID:
24590294
5.

Wharton's jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction.

Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y, Zhang HY.

Coron Artery Dis. 2013 Nov;24(7):549-58. doi: 10.1097/MCA.0b013e3283640f00.

PMID:
23892469
6.

Intravenous vs intraperitoneal transplantation of umbilical cord mesenchymal stem cells from Wharton's jelly in the treatment of streptozotocin-induced diabetic rats.

El-Hossary N, Hassanein H, El-Ghareeb AW, Issa H.

Diabetes Res Clin Pract. 2016 Nov;121:102-111. doi: 10.1016/j.diabres.2016.09.008. Epub 2016 Sep 21.

PMID:
27693839
7.

Overexpression of apelin in Wharton' jelly mesenchymal stem cell reverses insulin resistance and promotes pancreatic β cell proliferation in type 2 diabetic rats.

Gao LR, Zhang NK, Zhang Y, Chen Y, Wang L, Zhu Y, Tang HH.

Stem Cell Res Ther. 2018 Dec 7;9(1):339. doi: 10.1186/s13287-018-1084-x. Erratum in: Stem Cell Res Ther. 2019 Jan 8;10(1):6.

8.

Treatment With Human Wharton's Jelly-Derived Mesenchymal Stem Cells Attenuates Sepsis-Induced Kidney Injury, Liver Injury, and Endothelial Dysfunction.

Cóndor JM, Rodrigues CE, Sousa Moreira Rd, Canale D, Volpini RA, Shimizu MH, Camara NO, Noronha Ide L, Andrade L.

Stem Cells Transl Med. 2016 Aug;5(8):1048-57. doi: 10.5966/sctm.2015-0138. Epub 2016 Jun 8.

9.

Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton's Jelly mesenchymal stem cells after myocardial infarction.

Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H.

Chin Med J (Engl). 2012 Oct;125(19):3472-8.

PMID:
23044308
10.

A comparison of Wharton's jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.

El-Demerdash RF, Hammad LN, Kamal MM, El Mesallamy HO.

Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6.

PMID:
26541176
11.

Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells.

Kim MJ, Shin KS, Jeon JH, Lee DR, Shim SH, Kim JK, Cha DH, Yoon TK, Kim GJ.

Cell Tissue Res. 2011 Oct;346(1):53-64. doi: 10.1007/s00441-011-1249-8. Epub 2011 Oct 11.

PMID:
21987220
12.

Application potential of mesenchymal stem cells derived from Wharton's jelly in liver tissue engineering.

Zhang L, Zhao YH, Guan Z, Ye JS, de Isla N, Stoltz JF.

Biomed Mater Eng. 2015;25(1 Suppl):137-43. doi: 10.3233/BME-141232. Review.

PMID:
25538064
13.

Role of Nonmuscle Myosin II in Migration of Wharton's Jelly-Derived Mesenchymal Stem Cells.

Arora S, Saha S, Roy S, Das M, Jana SS, Ta M.

Stem Cells Dev. 2015 Sep 1;24(17):2065-77. doi: 10.1089/scd.2015.0095. Epub 2015 Jun 4.

14.

Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.

El-Asfar RK, Kamal MM, Abd El-Razek RS, El-Demerdash E, El-Mesallamy HO.

Cell Tissue Res. 2018 Apr;372(1):91-98. doi: 10.1007/s00441-017-2725-6. Epub 2017 Nov 20.

PMID:
29159483
15.

The alleviation of acute and chronic kidney injury by human Wharton's jelly-derived mesenchymal stromal cells triggered by ischemia-reperfusion injury via an endocrine mechanism.

Du T, Cheng J, Zhong L, Zhao XF, Zhu J, Zhu YJ, Liu GH.

Cytotherapy. 2012 Nov;14(10):1215-27. doi: 10.3109/14653249.2012.711471. Epub 2012 Aug 27.

PMID:
22920838
16.

Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes.

Hu J, Wang Y, Gong H, Yu C, Guo C, Wang F, Yan S, Xu H.

Exp Ther Med. 2016 Sep;12(3):1857-1866. Epub 2016 Jul 26.

17.

Association of expression levels of pluripotency/stem cell markers with the differentiation outcome of Wharton's jelly mesenchymal stem cells into insulin producing cells.

Kassem DH, Kamal MM, El-Kholy Ael-L, El-Mesallamy HO.

Biochimie. 2016 Aug;127:187-95. doi: 10.1016/j.biochi.2016.05.019. Epub 2016 Jun 3.

PMID:
27265786
18.

Optimizing isolation culture and freezing methods to preserve Wharton's jelly's mesenchymal stem cell (MSC) properties: an MSC banking protocol validation for the Hellenic Cord Blood Bank.

Chatzistamatiou TK, Papassavas AC, Michalopoulos E, Gamaloutsos C, Mallis P, Gontika I, Panagouli E, Koussoulakos SL, Stavropoulos-Giokas C.

Transfusion. 2014 Dec;54(12):3108-20. doi: 10.1111/trf.12743. Epub 2014 Jun 4.

PMID:
24894363
19.

Preeclampsia enhances neuroglial marker expression in umbilical cord Wharton's jelly-derived mesenchymal stem cells.

Joerger-Messerli M, Brühlmann E, Bessire A, Wagner A, Mueller M, Surbek DV, Schoeberlein A.

J Matern Fetal Neonatal Med. 2015 Mar;28(4):464-9. doi: 10.3109/14767058.2014.921671. Epub 2014 Jun 5.

PMID:
24803009
20.

Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.

Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y.

Endocrine. 2014 Mar;45(2):279-87. doi: 10.1007/s12020-013-9984-0. Epub 2013 May 18.

PMID:
23686639

Supplemental Content

Support Center